Literature DB >> 1548080

Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.

C J Boylan1, W L Current.   

Abstract

An immunosuppressed rat model of Pneumocystis carinii pneumonia is described that utilizes simple, noninvasive intratracheal (i.t.) inoculation of cryopreserved parasites and results in development of severe P. carinii pneumonia within 5 weeks. This is an improvement over the most commonly used models of P. carinii pneumonia that rely on immune suppression to activate latent P. carinii infections and that often require 8 to 12 weeks to produce heavy infections of P. carinii. It is also less labor intensive than more recent models requiring surgical instillation of parasites. Our report describes a series of preliminary studies to select an appropriate strain of rat; to determine suitable methods for inducing uniform immunosuppression, P. carinii inoculation, and laboratory maintenance of P. carinii; and to determine effective animal husbandry methods for maintaining animals free from serious secondary infections. Results of our more detailed studies demonstrate that animals receiving two or three i.t. inoculations of approximately 10(6) cryopreserved P. carinii organisms have a predictable course of disease progression which includes moderate P. carinii infections within 3 weeks, severe P. carinii pneumonia in 5 weeks, and a high percentage of mortality due to P. carinii pneumonia in 6 weeks. Parasites were distributed evenly between the right and left lungs, regardless of the number of P. carinii inoculations administered. Non-P. carinii-inoculated immunosuppressed control rats maintained in microisolator cages remained free of P. carinii, thus providing an important control that is missing from many P. carinii pneumonia models. Most non-P. carinii-inoculated control animals and P. carinii-inoculated rats treated with trimethoprim-sulfamethoxazole that were housed in open caging in the same room containing heavily infected animals had no detectable infections after 5 to 6 weeks of immunosuppression; however, some had a small number of P. carinii in their lungs. Because heavy, reproducible infections are achieved 5 weeks after i.t. inoculation, because few animals are lost to secondary infections, and because animals can be maintained as noninfected contemporaneous controls, this animal model is useful for the maintenance of P. carinii strains, for studies of the transmission and natural history of P. carinii, for the production of large numbers of organisms for laboratory studies, and for the evaluation of potential anti-P. carinii drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548080      PMCID: PMC257034          DOI: 10.1128/iai.60.4.1589-1597.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

Review 1.  Prophylaxis of Pneumocystis carinii pneumonia: an update.

Authors:  J A Kovacs; H Masur
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

2.  Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  S K Jones; J E Hall; M A Allen; S D Morrison; K A Ohemeng; V V Reddy; J D Geratz; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Nude mouse: a new experimental model for Pneumocystis carinii infection.

Authors:  P D Walzer; V Schnelle; D Armstrong; P P Rosen
Journal:  Science       Date:  1977-07-08       Impact factor: 47.728

4.  New rat model of Pneumocystis carinii infection.

Authors:  M S Bartlett; J A Fishman; S F Queener; M M Durkin; M A Jay; J W Smith
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

5.  Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

Authors:  M S Bartlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  Exp Parasitol       Date:  1990-01       Impact factor: 2.011

6.  Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Experimental Pneumocystis carinii pneumonia in C3H/HeJ and C3HeB/FeJ mice.

Authors:  P D Walzer; M E Rutledge; K Yoneda
Journal:  J Reticuloendothel Soc       Date:  1983-01

8.  Metabolic and synthetic activities of Pneumocystis carinii in vitro.

Authors:  E L Pesanti; C Cox
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

10.  Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates.

Authors:  J A Kovacs; J L Halpern; B Lundgren; J C Swan; J E Parrillo; H Masur
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

View more
  28 in total

Review 1.  Genetics of surface antigen expression in Pneumocystis carinii.

Authors:  J R Stringer; S P Keely
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Pneumocystis carinii infection causes lung lesions historically attributed to rat respiratory virus.

Authors:  Robert S Livingston; Cynthia L Besch-Williford; Matthew H Myles; Craig L Franklin; Marcus J Crim; Lela K Riley
Journal:  Comp Med       Date:  2011-02       Impact factor: 0.982

3.  Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.

Authors:  M T Cushion; M Collins; B Hazra; E S Kaneshiro
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Characterizations of neutral lipid fatty acids and cis-9,10-epoxy octadecanoic acid in Pneumocystis carinii carinii.

Authors:  E S Kaneshiro; J E Ellis; Z Guo; K Jayasimhulu; J N Maiorano; K A Kallam
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

5.  The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii.

Authors:  A L Laursen; S C Mogensen; H M Andersen; P L Andersen; S Ellermann-Eriksen
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 6.  The ecology of pneumocystis: perspectives, personal recollections, and future research opportunities.

Authors:  Peter D Walzer
Journal:  J Eukaryot Microbiol       Date:  2013-09-03       Impact factor: 3.346

7.  Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.

Authors:  M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.

Authors:  M S Bartlett; W L Current; M P Goheen; C J Boylan; C H Lee; M M Shaw; S F Queener; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Phospholipid composition of Pneumocystis carinii carinii and effects of methylprednisolone immunosuppression on rat lung lipids.

Authors:  Z Guo; E S Kaneshiro
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

10.  Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study.

Authors:  Elodie Senggen Manoloff; Patrick Francioli; Patrick Taffé; Guy Van Melle; Jacques Bille; Philippe M Hauser
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.